From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease

Last Updated: Wednesday, May 17, 2023

Results from a phase I trial demonstrate that fostamatinib, a spleen tyrosine kinase inhibitor, has a manageable safety profile post alloHCT and an overall response rate of 77% in patients with steroid-refractory chronic GVHD.

Translation and Cellular Therapy
Advertisement
News & Literature Highlights
Advertisement
Advertisement